# Nexalin Therapy for the Treatment of Depressive Symptoms

> **NCT00774813** · PHASE2 · COMPLETED · sponsor: **Kalaco Scientific, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Depression

## Interventions

- **DEVICE:** Nexalin 1.3mA Device
- **DEVICE:** Nexalin 15mA device
- **DRUG:** placebo device and Citalopram

## Key facts

- **NCT ID:** NCT00774813
- **Lead sponsor:** Kalaco Scientific, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2008-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00774813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00774813, "Nexalin Therapy for the Treatment of Depressive Symptoms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00774813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*